|1.||Yano, Ikuya: 4 articles (02/2014 - 03/2010)|
|2.||Akaza, Hideyuki: 3 articles (02/2014 - 10/2010)|
|3.||Matsumoto, Misako: 3 articles (07/2010 - 05/2005)|
|4.||Seya, Tsukasa: 3 articles (07/2010 - 05/2005)|
|5.||Azuma, Ichiro: 3 articles (12/2009 - 07/2004)|
|6.||Azuma, I: 3 articles (06/2008 - 01/2001)|
|7.||Nakaya, Akihiro: 2 articles (02/2014 - 11/2011)|
|8.||Nakamura, Takashi: 2 articles (02/2014 - 11/2011)|
|9.||Harashima, Hideyoshi: 2 articles (02/2014 - 11/2011)|
|10.||Miyazaki, Jun: 2 articles (02/2014 - 11/2011)|
07/01/2004 - "In the present study, we demonstrated for the first time that WT1 peptide vaccination combined with Mycobacterium bovis bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) was more effective for eradication of WT1-expressing tumor cells that had been implanted into mice before vaccination (a "therapeutic" model) compared with WT1 peptide vaccination alone. "
09/01/1975 - "CW and cell-wall skeleton (CWS) preparations from Mycobacterium phlei, a fast-growing saprophyte of group IV of the atypical mycobacteria, suppressed tumor growth in essentially all animals when 37.5-mug doses were administered; at a dose of 300 mug, they cured 50-60% of the animals in regression tests. "
03/01/2007 - "To investigate the effects of Nocardia rubra cell wall skeleton (Nr-CWS) on the HeLa cell line, one of the cell lines of human cervical cancer, infected with HPV. "
12/15/2006 - "dendritic cell administration by combining dendritic cells stimulated with Bacillus Calmette-Guerin cell wall skeleton (BCG-CWS) additionally with cryoablative pretreatment of tumors and analyzed the therapeutic mechanisms. "
12/15/2006 - "Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation."
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/15/1986 - "Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogeneic AML cells."
03/01/1983 - "Chemoimmunotherapy for acute nonlymphocytic leukemia with BCG- and/or Nocardia rubra-cell wall skeleton (CWS). "
03/01/1983 - "Chemoimmunotherapy for acute nonlymphocytic leukemia with BCG-and/or Nocardia rubra-cell wall skeleton (CWS). "
12/01/1978 - "Chemoimmunotherapy of acute myelogenous leukemia with BCG-cell wall skeleton (CWS)."
04/01/1986 - "[Immunotherapy of acute myelogenous leukemia (AML) in adults with the Nocardia rubra cell wall skeleton]."
|3.||Lung Neoplasms (Lung Cancer)
02/01/1979 - "Effect of Nocardia rubra cell-wall skeleton on the induction of lung cancer in ACI/N rats."
01/01/1985 - "[Randomized controlled study on adjuvant immunotherapy for unresectable lung cancer with Nocardia rubra cell wall skeleton]."
11/01/1983 - "Randomized controlled study of adjuvant immunotherapy with Nocardia rubra cell wall skeleton for inoperable lung cancer."
04/01/1983 - "[Effect of adjuvant immunotherapy with Nocardia rubra cell-wall skeleton in lung cancer]."
02/01/1983 - "[Immunotherapy of resectable lung cancer using Nocardia rubra cell wall skeleton]."
|4.||Malignant Pleural Effusion
08/01/1983 - "The intrapleural injection of BCG cell wall skeleton (BCG-CWS) is thought to be beneficial in the treatment of malignant pleural effusion. "
01/01/1987 - "The ability of Nocardia rubra cell wall skeleton (N-CWS) to augment macrophage cytotoxicity function was examined using human pleural macrophages prepared from 32 malignant pleural effusions and 53 pleural washings. "
08/01/1984 - "A randomized controlled study of intrapleural instillation of Adriamycin (control group, 30 patients) and Adriamycin Nocardia rubra cell wall skeleton (N-CWS group, 26 patients) with tube thoracostomy was performed in 55 patients with malignant pleural effusion due to primary lung cancer. "
|5.||Melanoma (Melanoma, Malignant)
04/01/1995 - "Towards this end, we examined whether the immunogenicity of a melanoma vaccine could be potentiated by DETOX, an adjuvant consisting of monophosphoryl lipid A (MPL) and purified mycobacterial cell-wall skeleton (CWS). "
10/15/1991 - "AM were incubated for 16 h in medium with various macrophage activators [lipopolysaccharide, des-methyl muramyldipeptide, Nocardia rubra cell wall skeleton, and heptanoyl-gamma-D-Glu-(L)-meso-alpha,epsilon-A2pm(L)-D-Al aOH] in the presence or absence of IL-4, and then their tumoricidal activity was assayed by measuring 125I-UdR release from human melanoma (A375) cells. "
09/04/1991 - "We examined the effect of a new adjuvant consisting of purified mycobacterial cell wall skeleton (CWS) and monophosphoryl lipid A (MPL) on the immunogenicity of a murine melanoma vaccine. "
08/01/1979 - "The clinical efficacy of intralesional immunotherapy utilizing Mycobacterium smegmatis cell wall skeleton (CWS) and trehalose dimycolate attached to oil droplets was investigated in 15 patients with advanced malignant melanoma. "
08/01/1979 - "Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3)."
|1.||Nocardia cell wall skeleton
|2.||monophosphoryl lipid A